Balyasny Asset Management L.P. Boosts Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Balyasny Asset Management L.P. grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 77.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 110,851 shares of the medical instruments supplier's stock after acquiring an additional 48,522 shares during the period. Balyasny Asset Management L.P. owned about 0.27% of AngioDynamics worth $1,015,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ANGO. Barclays PLC raised its stake in AngioDynamics by 81.0% during the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier's stock worth $651,000 after buying an additional 37,394 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after acquiring an additional 123,271 shares during the period. Moody National Bank Trust Division grew its position in shares of AngioDynamics by 70.2% during the 4th quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier's stock valued at $511,000 after acquiring an additional 23,003 shares during the period. SG Americas Securities LLC grew its position in shares of AngioDynamics by 21.3% during the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock valued at $147,000 after acquiring an additional 2,832 shares during the period. Finally, R Squared Ltd bought a new position in shares of AngioDynamics during the 4th quarter valued at approximately $49,000. Institutional investors own 89.43% of the company's stock.

AngioDynamics Trading Down 0.1%

Shares of ANGO stock traded down $0.01 during trading on Tuesday, reaching $9.58. 9,371 shares of the company's stock traded hands, compared to its average volume of 552,465. The company has a market capitalization of $389.02 million, a P/E ratio of -1.70 and a beta of 0.58. The firm's 50-day moving average is $9.45 and its 200 day moving average is $9.44. AngioDynamics, Inc. has a 1 year low of $5.47 and a 1 year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.00 million for the quarter, compared to analysts' expectations of $70.30 million. AngioDynamics's quarterly revenue was down 4.3% compared to the same quarter last year. As a group, sell-side analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $16.00 target price (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.